𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

✍ Scribed by F. Stagno; P. Vigneri; V. Del Fabro; S. Stella; M. Massimino; S. Berretta; A. Messina; F. Di Raimondo

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
82 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Achievement of complete molecular respon
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Ros πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 109 KB

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cas

Cytogenetic and molecular responses in c
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non